Leukotriene Modifiers Global Market Report 2024

The leukotriene modifiers market size has grown strongly in recent years. It will grow from $21.04 billion in 2023 to $22.33 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to several factors, including the growing impact of regulatory approvals, increased awareness among healthcare professionals and patients about the benefits of leukotriene modifiers, expiration of patents for certain leukotriene modifier drugs allowing for the entry of generic versions, expansion of indications for leukotriene modifiers, and growing collaborations between pharmaceutical companies and healthcare organizations.

The leukotriene modifiers market size is expected to see strong growth in the next few years. It will grow to $28.48 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to significant opportunities in emerging markets driven by increasing healthcare infrastructure and rising disposable incomes, a shift towards personalized medicine, growing adoption of telemedicine and remote patient monitoring, ongoing research and development focused on novel drug candidates and formulations, and anticipated changes in regulatory frameworks. Major trends expected during this period include the integration of digital health technologies such as mobile apps and wearable devices, incorporation of artificial intelligence (AI) and machine learning algorithms, exploration of novel therapeutic targets, development of patient engagement solutions and tools, and adoption of continuous manufacturing processes for enhanced efficiency and flexibility in drug production.

The increasing prevalence of asthma and allergic conditions is poised to drive the growth of the leukotriene modifier market in the future. Asthma and allergic conditions encompass a range of immune system hypersensitivity disorders triggered by various allergens, leading to inflammation and related symptoms. The rise in asthma and allergic conditions can be attributed to factors such as heightened exposure to pollutants, changing climate patterns, rising temperatures, and increased population density. Leukotriene modifiers play a crucial role in managing and alleviating symptoms associated with asthma and allergic conditions. They also improve respiratory function, reduce inflammation, and offer a safer and more effective treatment option for individuals with chronic respiratory issues. For example, data published by the National Center for Health Statistics (NCHS) in May 2024 indicated an increase in the prevalence of current asthma among adults aged 18 and over in the United States, from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes within the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. Therefore, the rising incidence of asthma and allergic conditions is a key driver for the leukotriene modifier market.

Major companies in the leukotriene modifier market are concentrating on developing generic formulations, including extended-release (ER) tablets, to broaden their product offerings and meet the growing demand for more convenient and efficient treatments. Generic extended-release (ER) tablets are designed to gradually release active ingredients over an extended period, offering improved dosing schedules and convenience compared to immediate-release formulations. For instance, Camber Pharmaceuticals Inc. added Zileuton ER Tablets to its portfolio in April 2023. These tablets are indicated for asthma prophylaxis and chronic treatment in adults and children aged 12 years and older. They are not meant for acute asthma attack reversal but can be continued during such exacerbations. Zileuton ER Tablets are available in 600 mg strength in 120-count bottles.

In April 2023, SK Capital Partners LP acquired Apotex Pharmaceutical Holdings Inc. to leverage its renowned brand, diverse product portfolio, global presence, and skilled team for growth and shareholder value enhancement. Apotex Pharmaceutical Holdings Inc., based in Canada, manufactures leukotriene modifiers such as Montelukast drugs.

Major companies operating in the leukotriene modifiers market are Merck And Co., Sanofi SA, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Limited, Sun Pharmaceutical Industries, Sumitomo Dainippon Pharma, Chiesi Farmaceutici S.p.A., Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Apotex Pharmaceutical Holdings Inc., Torrent Pharmaceuticals Ltd., DAVA Pharmaceuticals, Alembic Pharmaceuticals Ltd., Starallergens Greer Ltd, Lannett Company, Accord Healthcare, Jubilant Life Sciences Ltd., Aytu BioScience, Annett Company Inc.

North America was the largest region in the leukotriene modifiers market in 2023. The regions covered in the leukotriene modifiers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the leukotriene modifiers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Leukotriene modifiers are a class of medications used to manage and treat allergic rhinitis (hay fever) and asthma by blocking the action or production of leukotrienes in the body. Leukotrienes are chemicals that contribute to inflammation, bronchoconstriction (narrowing of the airways), and mucus production associated with these conditions. By inhibiting leukotrienes, these medications help reduce symptoms such as wheezing, shortness of breath, and nasal congestion.

The main types of leukotriene modifiers include montelukast, zafirlukast, zileuton er, and zileuton. Montelukast, for instance, is a leukotriene receptor antagonist used to prevent and manage asthma and relieve symptoms of seasonal allergies. These medications are available in various forms such as tablets, chewable tablets, and oral granules, and are distributed through channels such as hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

The leukotriene modifiers market research report is one of a series of new reports that provides leukotriene modifiers market statistics, including leukotriene modifiers industry global market size, regional shares, competitors with an leukotriene modifiers market share, detailed leukotriene modifiers market segments, market trends and opportunities, and any further data you may need to thrive in the leukotriene modifiers industry. This leukotriene modifiers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leukotriene modifiers market consists of sales of modafinil, armodafinil, amphetamine-based stimulants, fluoxetine, and sertraline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.